Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Shares Outstanding (Weighted Average) (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $30.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 133.16% to $30.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.5 million through Dec 2025, up 133.16% year-over-year, with the annual reading at $30.5 million for FY2025, 133.16% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $30.5 million in Q4 2025 for Insight Molecular Diagnostics, up from $29.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $92.2 million in Q1 2022 to a low of $5135.0 in Q2 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $23.2 million across 5 years, with a median of $9.4 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 99.99% in 2022 and later skyrocketed 136803.6% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $88920.0 in 2021, then skyrocketed by 6130.32% to $5.5 million in 2022, then skyrocketed by 38.1% to $7.7 million in 2023, then surged by 70.84% to $13.1 million in 2024, then surged by 133.16% to $30.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IMDX at $30.5 million in Q4 2025, $29.9 million in Q3 2025, and $32.0 million in Q2 2025.